Navigation Links
Promising results shown for kidney cancer drug
Date:2/4/2010

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.

"Advanced renal cell carcinoma remains a challenging disease, but the outlook for patients has improved in the past year including the addition of pazopanib, which targets multiple pathways within cancer cells," study author Dr. Cora N. Sternberg, chief of the medical oncology department at the San Camillo and Forlanini Hospital in Rome, Italy, said in a news release from the American Society of Clinical Oncology.

Dr. Sternberg also serves as the director of the scientific advisory board for the Columbus Cancer Foundation (http://columbuscancerfoundation.org/CCF/Institution.html), a international nonprofit organization devoted to supporting basic cancer research.

Pazopanib inhibits the development of blood vessels that tumors need to grow and spread.

"These clinical findings are indeed very encouraging," said Dr. Antonio Giordano, M.D., Ph.D., the founder and director of the Sbarro Health Research Organization located at Temple University in Philadelphia, PA. "We will look forward to the further studies which are currently evaluating the impact of pazopanib on the overall survival of treated patients."

In a phase 3 study, 233 patients with previously untreated locally advanced or metastastic kidney cancer and 202 other patients with kidney cancer who had been previously treated with interleukin or interferon, were randomly assigned to receive the oral drug pazopanib or a placebo.

Results showed that the time it took for a patient's disease to progress was more than double for the group receiving pazopanib (9.2 months), compared with the placebo group (4.2 months). The most dramatic effect was seen in previously untreated patients (11.1 months for the pazopanib group vs. 2.8 for the placebo) and persisted among those previously treated (7.4 vs. 4.2 months, respectively). The study is ongoing to determine how the drug impacts overall survival.

Common side effects of pazopanib included diarrhea (52 percent), hypertension (40 percent), hair color changes (38 percent), nausea (26 percent), weight loss (22 percent) and vomiting (21 percent).


'/>"/>

Contact: Ilene Rush
irush@shro.org
215-635-5162
Sbarro Health Research Organization
Source:Eurekalert

Related biology news :

1. UIC researchers find promising new targets for antibiotics
2. New book defines promising young field of adult neurogenesis
3. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
4. Cancer and arthritis therapy may be promising treatment for diabetes
5. Unique whey protein is promising supplement for strict PKU diet
6. Promising new drug targets identified for Huntingtons disease
7. Promising new nanotechnology for spinal cord injury
8. Biodesigns Rittmann offers promising perspectives on societys energy challenge
9. UIC researchers make promising finding in severe lung disease
10. New treatment approach promising for lymphoma patients in the developing world
11. Immunotherapy in high-risk pediatric sarcomas shows promising response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology: